April 3, 2024

BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs

Learn More
As regenerative approaches enter mainstream clinical pathways, BellaSeno is helping shape the future of soft-tissue restoration.
Privacy PolicyImprintContact Us

Contact

Deutscher Platz 5A
04103 Leipzig
Germany
 
4 Starling Street
Burliegh Heads
QLD, Australia, 4220

*Data on file. BRV-004 and Animal Trial Report

The product in not commercially available at this date in time.
Images are illustrative only and do not directly represent the scaffold or clinical outcomes.
‍
All rights reserved
Copyright 2026
BELLASENO GmbH